IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars

Brands

Yourlist
Quizie
FaithTap
Blessed
All brands

Genentech-DualityBio Global ADC Deal Over $1BBusiness — Aug 28, 2026DualityBio and Genentech (Roche) have launched a global collaboration to develop next-generation antibody-drug conjugates using the DUPAC payload platform, featuring a $45 million upfront and potential milestones exceeding $1 billion, with DualityBio leading early discovery and Genentech obtaining exclusive worldwide rights after Phase 1a. The program targets tumors resistant to current topoisomerase-inhibitor–based ADCs, backed by preclinical data and potential expansion into China via the Dupac platform.

Hanmi Genentech obesity drug deal worth $2.3B reported — Aug 24, 2026Hanmi Pharmaceutical has signed an exclusive, worldwide license with Genentech for HM17321, a long-acting UCN2 analog aimed at obesity that promises weight loss with muscle preservation, with Genentech taking over development from Phase 2 onward outside Korea. The deal could reach about $2.3 billion, including a $190 million upfront, up to $2.1 billion in milestones, and future royalties, subject to U.S. antitrust clearance and successful clinical progression.

BioNTech halts Phase 2 cancer vaccine trialHealth — Aug 28, 2026BioNTech and Genentech/Roche have terminated the Phase 2 trial of autogene cevumeran for ctDNA-positive, surgically resected high-risk colorectal cancer after an independent DSMB cited a numerical survival imbalance, with further continuation deemed unlikely to change outcomes. The company will analyze the data to refine patient selection, and a separate Phase 2 trial in pancreatic cancer remains ongoing.